The U.S. government’s newly announced pharmaceutical tariff plan is creating turbulence across the drug supply chain leaving pharmaceutical companies, compliance officers, and trade professionals scrambling for clarity. This policy took effect October 1, and the lack of detail has raised more questions than answers.
A 100% Tariff on Branded Drugs
Under the new rule, branded and patented drugs will face a 100% tariff unless the manufacturer can demonstrate that it has a US-based pharmaceutical facility under construction or recently begun. Generics, which make up the majority of US prescriptions, are notably exempt, as are drugs produced in the European Union, though EU medicines will still be subject to a 15% tariff.
This carveout places much of the pressure on Asian drugmakers, particularly in Japan, South Korea, and China, whose branded products are not covered by existing trade agreements. Markets reacted accordingly, with US and European pharmaceutical stocks remaining steady while their Asian counterparts slipped.
The announcement has left health care lawyers, trade experts, and manufacturers alike asking fundamental questions:
- If a company already has US facilities, are they exempt, or does expansion need to be underway?
- Does producing one drug domestically shield all of a company’s products from tariffs, or is the exemption applied drug by drug?
- How will Customs and Border Protection enforce the distinction between branded and generic drugs, especially when HTS (Harmonized Tariff Schedule) codes do not make that distinction?
These compliance ambiguities create significant risks for pharmaceutical importers. For companies with complex supply chains spanning multiple geographies, the uncertainty could lead to shipment delays, disputes over tariff classification, or sudden cost surges.
Timing with Other Policy Moves
The rollout of these tariffs comes at a moment of heightened regulatory activity in health care. Drugmakers are simultaneously contending with:
- Medicare negotiations under the Inflation Reduction Act (IRA), which target branded drugs without generics or biosimilars.
- A pending Section 232 investigation into the national security risks of pharmaceutical imports, which could give these tariffs additional durability if the findings support the move.
Additionally comes President Trump’s “Most Favored Nation” executive order, requiring US drug prices to match the lowest global price of other comparably developed countries. By September 29, pharmaceutical companies were required to respond to the executive order, “Reducing Drug Prices for Americans and Taxpayers.” The order demands that drugmakers:
- Provide preferential pricing to all Medicaid patients
- Explore direct-to-consumer sales channels
- Support trade policies that raise drug prices abroad, with the intent of reinvesting that revenue into lowering US prices
Some companies like Pfizer and Eli Lilly are already adapting and have launched direct-to-consumer programs.
What This Means for Supply Chain and Trade Compliance Professionals
For compliance and supply chain leaders, this is a reminder of just how volatile the pharmaceutical trade environment has become. Key priorities include:
- Scenario modeling: Running cost and sourcing models to prepare for tariffs that may apply unevenly across portfolios.
- Visibility into suppliers: Ensuring transparency into where branded drugs are produced and whether exemptions apply.
- HS code scrutiny: Monitoring for any upcoming changes or clarifications that attempt to separate branded from generic classifications.
- Policy tracking: Staying alert to potential shifts tied to Section 232 outcomes, IRA negotiations, and executive orders that may overlap or conflict.
How Quickcode Helps
At Quickcode.ai, we specialize in making sense of evolving trade policies and reducing the compliance burden on global manufacturers. Our platform helps companies:
- Automate HS/HTS code classification, reducing risks of misclassification during tariff enforcement.
- Track regulatory changes in real time, so you’re never caught off guard.
- Identify supply chain vulnerabilities and model the financial impacts of new tariffs.
While trade policy is being used as a catalyst for domestic manufacturing, pharmaceutical companies cannot afford uncertainty. By combining automation with behavioral science-driven design, Quickcode ensures compliance teams stay one step ahead from any potential sudden shocks.